Mater Private Hospital
Dublin, Ireland
8 recruiting
Showing 1–8 of 8 trials
Recruiting
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
Atrial FibrillationPulsed Field AblationFARAPULSE
Boston Scientific Corporation500 enrolled32 locationsNCT06808217
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled383 locationsNCT05253651
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.420 enrolled129 locationsNCT06881784
Recruiting
Not Applicable
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
Atrial FibrillationAtrial ArrhythmiaPersistent Atrial Fibrillation+1 more
Abbott Medical Devices300 enrolled22 locationsNCT07181590
Recruiting
Not Applicable
Randomised Trial of Dual Device Treatment Involving Drug-coated Balloon Angioplasty and Drug-eluting Stent Implantation Compared to Single Device Treatments in Patients With Diabetes Mellitus
Diabetes MellitusCoronary Arterial Disease (CAD)de Novo Coronary Lesions+1 more
Royal College of Surgeons, Ireland120 enrolled1 locationNCT07303439
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
Phase 3
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Prostate Cancer Metastatic
UNICANCER300 enrolled90 locationsNCT04916613